Deal Tracker · Countries

Saudi Arabia pharma deals

69 pharma deals involving Saudi Arabia — companies based there or deals covering the market — tracked by EPT: licensing, distribution & localization. Most active: Jamjoom Pharma, SPIMACO, ADCAN Pharma & Avalon Pharma. Latest: Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).

69
deals tracked
48
announced in 2026
$521.7m
disclosed value (6 deals)
35%
licensing, the top deal type
  • EPT has tracked 69 Saudi Arabia pharma deals (2014–2026), 48 of them announced in 2026.
  • The most common structures are licensing (35%), distribution (20%) & localization (14%).
  • Values were disclosed for 6 of 69 deals, totalling $521.7m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).
  • The most active companies: Jamjoom Pharma (7), SPIMACO (7), ADCAN Pharma (6) & Avalon Pharma (5).

Countries involved

UAE (20) · China (10) · Egypt (8) · Oman (8) · Bahrain (7) · Kuwait (7)

Largest disclosed deals

Questions

How many Saudi Arabia pharma deals has EPT tracked?
69 as of 12 Nov 2026, covering 2014–2026; 48 were announced in 2026. The most recent is Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).
What types of Saudi Arabia pharma deals are most common?
Licensing: 24 (35%); Distribution: 14 (20%); Technology transfer / Localization: 10 (14%); Partnership / Collaboration: 8 (12%).
Which companies are most active in Saudi Arabia pharma deals?
Jamjoom Pharma (7 deals), SPIMACO (7 deals), ADCAN Pharma (6 deals), Avalon Pharma (5 deals), Local Content and Government Procurement Authority (5 deals), Tabuk Pharmaceuticals (5 deals).
What is the largest disclosed Saudi Arabia pharma deal?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Oman Investment Authority → Oryx Isotopes: $17m (Joint venture, 8 Nov 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)